Share Price and Basic Stock Data
Last Updated: February 10, 2026, 8:53 pm
| PEG Ratio | -4.66 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
India Glycols Ltd operates in the chemicals sector, focusing on organic alcohol-based products. The company reported a price of ₹864 and a market capitalization of ₹5,807 Cr. In the fiscal year ending March 2023, sales stood at ₹2,651 Cr, which represented a decline compared to ₹2,868 Cr in the previous fiscal year. However, the latest quarterly results indicate a positive trend, with sales rising to ₹775 Cr in September 2023, and projected to reach ₹904 Cr by December 2023. This growth trajectory demonstrates an upward momentum in demand and operational efficiency. The company’s operating profit margin (OPM) has fluctuated, recording 12% in September 2023, down from 15% in June 2023. Nevertheless, the company aims to enhance its revenue streams, as reflected in the projected sales figures for the upcoming quarters, which suggest a return to growth with a target of ₹926 Cr by March 2024. Overall, the revenue trends indicate both challenges and opportunities for India Glycols as it positions itself within a competitive market landscape.
Profitability and Efficiency Metrics
India Glycols Ltd’s profitability metrics reflect a mixed performance. The company reported a net profit of ₹259 Cr, translating to a P/E ratio of 22.4, indicating a reasonable valuation relative to its earnings. The return on equity (ROE) stood at 11.1%, while the return on capital employed (ROCE) was recorded at 12.4%. These figures are slightly below the industry average, suggesting room for improvement in capital efficiency. The operating profit for the September 2023 quarter was ₹96 Cr, with an OPM of 12%, showcasing effective cost management despite rising expenses. The interest coverage ratio (ICR) of 3.20x indicates that the company can comfortably meet its interest obligations, although the rising trend in interest expenses, which reached ₹29 Cr in September 2023, requires monitoring. Furthermore, the cash conversion cycle (CCC) of 70 days suggests that the company has a relatively efficient working capital management process, essential for sustaining profitability in a volatile market.
Balance Sheet Strength and Financial Ratios
India Glycols Ltd’s balance sheet shows a solid foundation with reported reserves of ₹2,363 Cr against borrowings of ₹2,055 Cr, resulting in a debt-to-equity ratio of 0.79x. This indicates a balanced approach to leveraging, although the rising borrowings, which increased from ₹1,892 Cr in March 2025, warrant attention. The company’s total assets stood at ₹6,176 Cr, reflecting a steady growth in asset base, which is crucial for supporting operational activities. The book value per share increased to ₹728.61, providing a cushion for shareholder value. Additionally, the current ratio of 0.78x suggests a potential liquidity challenge, as it falls below the ideal benchmark of 1. However, the inventory turnover ratio of 3.31x indicates effective inventory management. These financial ratios collectively illustrate a stable balance sheet, although the company must navigate its liquidity position carefully while managing its debt levels to maintain financial health.
Shareholding Pattern and Investor Confidence
The shareholding pattern of India Glycols Ltd reflects a diverse investor base, with promoters holding 59.63% of the shares, indicating strong insider confidence. The public shareholding stood at 32.86%, while foreign institutional investors (FIIs) and domestic institutional investors (DIIs) accounted for 2.45% and 5.05%, respectively. The recent increase in the number of shareholders to 54,774 indicates growing interest in the stock, as the company continues to attract retail investors. However, the slight decline in promoter shareholding from 61.02% earlier in the year may raise concerns about long-term commitment. The stability of the DII shareholding, along with the fluctuating FII interests, suggests a cautious yet engaged market perspective. Overall, the distribution of shareholding underscores a mix of confidence and caution among investors, reflecting the company’s ongoing efforts to enhance value and performance.
Outlook, Risks, and Final Insight
The outlook for India Glycols Ltd appears cautiously optimistic, driven by projected revenue growth and improving profitability metrics. However, several risks could impact performance, including rising raw material costs and increasing competition in the chemicals sector. The company’s ability to manage operational costs effectively will be crucial in maintaining margins amid these challenges. Additionally, the liquidity position, indicated by the current ratio of 0.78x, necessitates close monitoring to avoid potential cash flow issues. On the upside, if the company can capitalize on emerging market opportunities and improve its operational efficiencies, it could enhance its profitability and shareholder returns. The combination of a solid balance sheet and a diverse investor base presents a robust platform for growth, positioning India Glycols for potential success in the evolving chemicals landscape. As such, stakeholders should remain vigilant to both the opportunities and challenges that lie ahead.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Aeonx Digital Technology Ltd | 65.3 Cr. | 142 | 242/121 | 29.2 | 115 | 0.70 % | 9.78 % | 6.79 % | 10.0 |
| Kanoria Chemicals & Industries Ltd | 336 Cr. | 77.2 | 104/64.8 | 122 | 0.00 % | 2.33 % | 11.8 % | 5.00 | |
| India Glycols Ltd | 6,649 Cr. | 991 | 1,223/502 | 24.6 | 357 | 0.50 % | 12.4 % | 11.1 % | 5.00 |
| Industry Average | 3,492.50 Cr | 403.40 | 26.90 | 198.00 | 0.40% | 8.17% | 9.90% | 6.67 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 670 | 554 | 619 | 689 | 775 | 904 | 926 | 969 | 961 | 975 | 863 | 1,040 | 1,092 |
| Expenses | 602 | 487 | 523 | 589 | 679 | 802 | 822 | 843 | 845 | 852 | 717 | 891 | 935 |
| Operating Profit | 68 | 67 | 96 | 100 | 96 | 102 | 105 | 126 | 116 | 124 | 146 | 150 | 158 |
| OPM % | 10% | 12% | 16% | 15% | 12% | 11% | 11% | 13% | 12% | 13% | 17% | 14% | 14% |
| Other Income | 9 | 35 | 6 | 12 | 12 | 9 | 10 | 14 | 15 | 19 | 13 | 20 | 14 |
| Interest | 24 | 27 | 26 | 28 | 29 | 31 | 33 | 36 | 40 | 44 | 45 | 45 | 49 |
| Depreciation | 21 | 21 | 30 | 21 | 28 | 26 | 26 | 28 | 28 | 27 | 33 | 34 | 38 |
| Profit before tax | 31 | 53 | 46 | 64 | 50 | 54 | 56 | 76 | 63 | 71 | 82 | 91 | 84 |
| Tax % | 25% | 6% | 13% | 20% | 24% | 23% | 24% | 20% | 22% | 20% | 22% | 19% | 22% |
| Net Profit | 24 | 50 | 40 | 51 | 38 | 42 | 42 | 60 | 50 | 57 | 64 | 73 | 65 |
| EPS in Rs | 4.04 | 4.96 | 6.51 | 8.26 | 6.14 | 6.73 | 6.82 | 9.75 | 8.03 | 9.18 | 10.34 | 11.83 | 10.51 |
Last Updated: January 1, 2026, 8:46 am
Below is a detailed analysis of the quarterly data for India Glycols Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1,092.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,040.00 Cr. (Jun 2025) to 1,092.00 Cr., marking an increase of 52.00 Cr..
- For Expenses, as of Sep 2025, the value is 935.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 891.00 Cr. (Jun 2025) to 935.00 Cr., marking an increase of 44.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 158.00 Cr.. The value appears strong and on an upward trend. It has increased from 150.00 Cr. (Jun 2025) to 158.00 Cr., marking an increase of 8.00 Cr..
- For OPM %, as of Sep 2025, the value is 14.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 14.00%.
- For Other Income, as of Sep 2025, the value is 14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 20.00 Cr. (Jun 2025) to 14.00 Cr., marking a decrease of 6.00 Cr..
- For Interest, as of Sep 2025, the value is 49.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 45.00 Cr. (Jun 2025) to 49.00 Cr., marking an increase of 4.00 Cr..
- For Depreciation, as of Sep 2025, the value is 38.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 34.00 Cr. (Jun 2025) to 38.00 Cr., marking an increase of 4.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 84.00 Cr.. The value appears to be declining and may need further review. It has decreased from 91.00 Cr. (Jun 2025) to 84.00 Cr., marking a decrease of 7.00 Cr..
- For Tax %, as of Sep 2025, the value is 22.00%. The value appears to be increasing, which may not be favorable. It has increased from 19.00% (Jun 2025) to 22.00%, marking an increase of 3.00%.
- For Net Profit, as of Sep 2025, the value is 65.00 Cr.. The value appears to be declining and may need further review. It has decreased from 73.00 Cr. (Jun 2025) to 65.00 Cr., marking a decrease of 8.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 10.51. The value appears to be declining and may need further review. It has decreased from 11.83 (Jun 2025) to 10.51, marking a decrease of 1.32.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:12 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,977 | 2,579 | 2,324 | 2,500 | 3,034 | 3,357 | 2,735 | 2,317 | 2,868 | 2,651 | 3,294 | 3,768 | 3,971 |
| Expenses | 2,774 | 2,455 | 2,149 | 2,263 | 2,712 | 2,941 | 2,433 | 2,026 | 2,599 | 2,346 | 2,879 | 3,247 | 3,394 |
| Operating Profit | 203 | 124 | 175 | 237 | 322 | 416 | 303 | 291 | 269 | 305 | 415 | 521 | 577 |
| OPM % | 7% | 5% | 8% | 9% | 11% | 12% | 11% | 13% | 9% | 12% | 13% | 14% | 15% |
| Other Income | -174 | -16 | -47 | 7 | 23 | 17 | 24 | 15 | 260 | 54 | 30 | 51 | 66 |
| Interest | 150 | 163 | 139 | 127 | 125 | 143 | 97 | 83 | 70 | 100 | 121 | 164 | 183 |
| Depreciation | 91 | 89 | 69 | 72 | 73 | 76 | 78 | 80 | 80 | 94 | 101 | 115 | 133 |
| Profit before tax | -212 | -144 | -81 | 45 | 147 | 213 | 153 | 143 | 379 | 165 | 223 | 292 | 327 |
| Tax % | -24% | -38% | -30% | 22% | 34% | 38% | 25% | 8% | 10% | 15% | 23% | 21% | |
| Net Profit | -161 | -89 | -57 | 35 | 97 | 133 | 115 | 132 | 340 | 141 | 173 | 231 | 259 |
| EPS in Rs | -26.07 | -14.32 | -9.18 | 5.66 | 15.59 | 21.42 | 18.52 | 21.26 | 54.90 | 20.21 | 27.95 | 37.31 | 41.86 |
| Dividend Payout % | -2% | 0% | 0% | 9% | 13% | 14% | 16% | 14% | 7% | 19% | 14% | 13% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 44.72% | 35.96% | 161.40% | 177.14% | 37.11% | -13.53% | 14.78% | 157.58% | -58.53% | 22.70% | 33.53% |
| Change in YoY Net Profit Growth (%) | 0.00% | -8.77% | 125.45% | 15.74% | -140.03% | -50.65% | 28.32% | 142.79% | -216.11% | 81.22% | 10.83% |
India Glycols Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 7% |
| 3 Years: | 10% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 12% |
| 3 Years: | 12% |
| TTM: | 34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 36% |
| 5 Years: | 43% |
| 3 Years: | 26% |
| 1 Year: | 29% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 10% |
| 3 Years: | 9% |
| Last Year: | 11% |
Last Updated: September 5, 2025, 7:00 am
Balance Sheet
Last Updated: December 4, 2025, 1:24 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 |
| Reserves | 341 | 266 | 687 | 721 | 814 | 932 | 1,003 | 1,138 | 1,761 | 1,870 | 2,020 | 2,225 | 2,363 |
| Borrowings | 2,053 | 2,264 | 1,236 | 1,095 | 834 | 1,000 | 999 | 1,137 | 1,047 | 1,112 | 1,348 | 1,892 | 2,055 |
| Other Liabilities | 818 | 593 | 1,665 | 1,645 | 1,742 | 1,821 | 2,053 | 1,814 | 1,792 | 1,845 | 2,218 | 2,029 | 1,709 |
| Total Liabilities | 3,243 | 3,154 | 3,620 | 3,492 | 3,421 | 3,784 | 4,086 | 4,119 | 4,631 | 4,858 | 5,617 | 6,176 | 6,157 |
| Fixed Assets | 1,309 | 1,146 | 2,029 | 2,111 | 2,156 | 2,173 | 2,228 | 2,193 | 2,318 | 2,717 | 3,205 | 3,829 | 3,754 |
| CWIP | 137 | 162 | 181 | 91 | 89 | 137 | 172 | 126 | 243 | 125 | 84 | 98 | 267 |
| Investments | 4 | 4 | 28 | 25 | 24 | 21 | 26 | 27 | 336 | 318 | 335 | 381 | 411 |
| Other Assets | 1,792 | 1,843 | 1,382 | 1,265 | 1,152 | 1,453 | 1,660 | 1,774 | 1,734 | 1,698 | 1,993 | 1,867 | 1,725 |
| Total Assets | 3,243 | 3,154 | 3,620 | 3,492 | 3,421 | 3,784 | 4,086 | 4,119 | 4,631 | 4,858 | 5,617 | 6,176 | 6,157 |
Below is a detailed analysis of the balance sheet data for India Glycols Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 31.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 31.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,363.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,225.00 Cr. (Mar 2025) to 2,363.00 Cr., marking an increase of 138.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,055.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1,892.00 Cr. (Mar 2025) to 2,055.00 Cr., marking an increase of 163.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,709.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,029.00 Cr. (Mar 2025) to 1,709.00 Cr., marking a decrease of 320.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 6,157.00 Cr.. The value appears to be improving (decreasing). It has decreased from 6,176.00 Cr. (Mar 2025) to 6,157.00 Cr., marking a decrease of 19.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3,754.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,829.00 Cr. (Mar 2025) to 3,754.00 Cr., marking a decrease of 75.00 Cr..
- For CWIP, as of Sep 2025, the value is 267.00 Cr.. The value appears strong and on an upward trend. It has increased from 98.00 Cr. (Mar 2025) to 267.00 Cr., marking an increase of 169.00 Cr..
- For Investments, as of Sep 2025, the value is 411.00 Cr.. The value appears strong and on an upward trend. It has increased from 381.00 Cr. (Mar 2025) to 411.00 Cr., marking an increase of 30.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,725.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,867.00 Cr. (Mar 2025) to 1,725.00 Cr., marking a decrease of 142.00 Cr..
- For Total Assets, as of Sep 2025, the value is 6,157.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6,176.00 Cr. (Mar 2025) to 6,157.00 Cr., marking a decrease of 19.00 Cr..
Notably, the Reserves (2,363.00 Cr.) exceed the Borrowings (2,055.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 201.00 | 122.00 | 174.00 | 236.00 | -512.00 | 415.00 | -696.00 | 290.00 | 268.00 | 304.00 | 414.00 | 520.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 54 | 62 | 57 | 57 | 40 | 35 | 76 | 57 | 51 | 59 | 43 | 35 |
| Inventory Days | 109 | 109 | 128 | 129 | 87 | 124 | 146 | 166 | 148 | 209 | 224 | 209 |
| Days Payable | 91 | 55 | 120 | 144 | 152 | 143 | 155 | 158 | 137 | 209 | 222 | 175 |
| Cash Conversion Cycle | 72 | 115 | 66 | 42 | -25 | 17 | 67 | 65 | 62 | 60 | 44 | 70 |
| Working Capital Days | -58 | -110 | -94 | -117 | -78 | -50 | -64 | -79 | -31 | -46 | -63 | -56 |
| ROCE % | 5% | 3% | 5% | 9% | 15% | 20% | 14% | 10% | 9% | 8% | 11% | 12% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| WhiteOak Capital Special Opportunities Fund | 59,954 | 0.43 | 6.09 | N/A | N/A | N/A |
| Samco Special Opportunities Fund | 42,362 | 3.02 | 4.3 | N/A | N/A | N/A |
| Samco Multi Cap Fund | 5,683 | 0.2 | 0.58 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 74.58 | 55.87 | 45.55 | 109.77 | 42.51 |
| Diluted EPS (Rs.) | 74.58 | 55.87 | 45.55 | 109.77 | 42.51 |
| Cash EPS (Rs.) | 96.81 | 83.04 | 72.23 | 128.95 | 68.15 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 728.61 | 662.44 | 614.12 | 572.46 | 377.41 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 728.61 | 662.44 | 614.12 | 572.46 | 377.41 |
| Revenue From Operations / Share (Rs.) | 1217.08 | 1063.89 | 856.18 | 926.41 | 748.35 |
| PBDIT / Share (Rs.) | 169.72 | 138.26 | 103.17 | 89.38 | 91.49 |
| PBIT / Share (Rs.) | 132.52 | 105.72 | 72.82 | 63.45 | 65.61 |
| PBT / Share (Rs.) | 79.43 | 66.74 | 49.62 | 112.44 | 38.68 |
| Net Profit / Share (Rs.) | 59.60 | 50.49 | 41.88 | 103.02 | 42.27 |
| NP After MI And SOA / Share (Rs.) | 74.58 | 55.87 | 40.40 | 109.77 | 42.51 |
| PBDIT Margin (%) | 13.94 | 12.99 | 12.04 | 9.64 | 12.22 |
| PBIT Margin (%) | 10.88 | 9.93 | 8.50 | 6.84 | 8.76 |
| PBT Margin (%) | 6.52 | 6.27 | 5.79 | 12.13 | 5.16 |
| Net Profit Margin (%) | 4.89 | 4.74 | 4.89 | 11.12 | 5.64 |
| NP After MI And SOA Margin (%) | 6.12 | 5.25 | 4.71 | 11.84 | 5.68 |
| Return on Networth / Equity (%) | 10.23 | 8.43 | 6.57 | 18.96 | 11.26 |
| Return on Capital Employeed (%) | 10.64 | 10.09 | 7.53 | 6.81 | 8.63 |
| Return On Assets (%) | 3.73 | 3.07 | 2.57 | 7.33 | 3.19 |
| Long Term Debt / Equity (X) | 0.46 | 0.35 | 0.28 | 0.30 | 0.43 |
| Total Debt / Equity (X) | 0.79 | 0.64 | 0.57 | 0.58 | 0.84 |
| Asset Turnover Ratio (%) | 0.63 | 0.62 | 0.55 | 0.68 | 0.55 |
| Current Ratio (X) | 0.78 | 0.81 | 0.88 | 0.91 | 0.96 |
| Quick Ratio (X) | 0.27 | 0.35 | 0.47 | 0.52 | 0.62 |
| Inventory Turnover Ratio (X) | 3.31 | 1.96 | 2.00 | 2.57 | 1.84 |
| Dividend Payout Ratio (NP) (%) | 10.72 | 13.42 | 18.56 | 5.46 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 7.15 | 8.48 | 10.60 | 4.42 | 0.00 |
| Earning Retention Ratio (%) | 89.28 | 86.58 | 81.44 | 94.54 | 0.00 |
| Cash Earning Retention Ratio (%) | 92.85 | 91.52 | 89.40 | 95.58 | 0.00 |
| Interest Coverage Ratio (X) | 3.20 | 3.55 | 3.20 | 3.97 | 3.40 |
| Interest Coverage Ratio (Post Tax) (X) | 2.12 | 2.30 | 2.02 | 2.25 | 2.30 |
| Enterprise Value (Cr.) | 5163.72 | 3526.29 | 2881.37 | 4053.87 | 2184.04 |
| EV / Net Operating Revenue (X) | 1.37 | 1.07 | 1.09 | 1.41 | 0.94 |
| EV / EBITDA (X) | 9.83 | 8.24 | 9.02 | 14.65 | 7.71 |
| MarketCap / Net Operating Revenue (X) | 0.91 | 0.71 | 0.71 | 1.09 | 0.55 |
| Retention Ratios (%) | 89.27 | 86.57 | 81.43 | 94.53 | 0.00 |
| Price / BV (X) | 1.52 | 1.14 | 0.99 | 1.75 | 1.10 |
| Price / Net Operating Revenue (X) | 0.91 | 0.71 | 0.71 | 1.09 | 0.55 |
| EarningsYield | 0.06 | 0.07 | 0.06 | 0.10 | 0.10 |
After reviewing the key financial ratios for India Glycols Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 74.58. This value is within the healthy range. It has increased from 55.87 (Mar 24) to 74.58, marking an increase of 18.71.
- For Diluted EPS (Rs.), as of Mar 25, the value is 74.58. This value is within the healthy range. It has increased from 55.87 (Mar 24) to 74.58, marking an increase of 18.71.
- For Cash EPS (Rs.), as of Mar 25, the value is 96.81. This value is within the healthy range. It has increased from 83.04 (Mar 24) to 96.81, marking an increase of 13.77.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 728.61. It has increased from 662.44 (Mar 24) to 728.61, marking an increase of 66.17.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 728.61. It has increased from 662.44 (Mar 24) to 728.61, marking an increase of 66.17.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,217.08. It has increased from 1,063.89 (Mar 24) to 1,217.08, marking an increase of 153.19.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 169.72. This value is within the healthy range. It has increased from 138.26 (Mar 24) to 169.72, marking an increase of 31.46.
- For PBIT / Share (Rs.), as of Mar 25, the value is 132.52. This value is within the healthy range. It has increased from 105.72 (Mar 24) to 132.52, marking an increase of 26.80.
- For PBT / Share (Rs.), as of Mar 25, the value is 79.43. This value is within the healthy range. It has increased from 66.74 (Mar 24) to 79.43, marking an increase of 12.69.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 59.60. This value is within the healthy range. It has increased from 50.49 (Mar 24) to 59.60, marking an increase of 9.11.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 74.58. This value is within the healthy range. It has increased from 55.87 (Mar 24) to 74.58, marking an increase of 18.71.
- For PBDIT Margin (%), as of Mar 25, the value is 13.94. This value is within the healthy range. It has increased from 12.99 (Mar 24) to 13.94, marking an increase of 0.95.
- For PBIT Margin (%), as of Mar 25, the value is 10.88. This value is within the healthy range. It has increased from 9.93 (Mar 24) to 10.88, marking an increase of 0.95.
- For PBT Margin (%), as of Mar 25, the value is 6.52. This value is below the healthy minimum of 10. It has increased from 6.27 (Mar 24) to 6.52, marking an increase of 0.25.
- For Net Profit Margin (%), as of Mar 25, the value is 4.89. This value is below the healthy minimum of 5. It has increased from 4.74 (Mar 24) to 4.89, marking an increase of 0.15.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.12. This value is below the healthy minimum of 8. It has increased from 5.25 (Mar 24) to 6.12, marking an increase of 0.87.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.23. This value is below the healthy minimum of 15. It has increased from 8.43 (Mar 24) to 10.23, marking an increase of 1.80.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.64. This value is within the healthy range. It has increased from 10.09 (Mar 24) to 10.64, marking an increase of 0.55.
- For Return On Assets (%), as of Mar 25, the value is 3.73. This value is below the healthy minimum of 5. It has increased from 3.07 (Mar 24) to 3.73, marking an increase of 0.66.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.46. This value is within the healthy range. It has increased from 0.35 (Mar 24) to 0.46, marking an increase of 0.11.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.79. This value is within the healthy range. It has increased from 0.64 (Mar 24) to 0.79, marking an increase of 0.15.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.63. It has increased from 0.62 (Mar 24) to 0.63, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1.5. It has decreased from 0.81 (Mar 24) to 0.78, marking a decrease of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has decreased from 0.35 (Mar 24) to 0.27, marking a decrease of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.31. This value is below the healthy minimum of 4. It has increased from 1.96 (Mar 24) to 3.31, marking an increase of 1.35.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 10.72. This value is below the healthy minimum of 20. It has decreased from 13.42 (Mar 24) to 10.72, marking a decrease of 2.70.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 7.15. This value is below the healthy minimum of 20. It has decreased from 8.48 (Mar 24) to 7.15, marking a decrease of 1.33.
- For Earning Retention Ratio (%), as of Mar 25, the value is 89.28. This value exceeds the healthy maximum of 70. It has increased from 86.58 (Mar 24) to 89.28, marking an increase of 2.70.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 92.85. This value exceeds the healthy maximum of 70. It has increased from 91.52 (Mar 24) to 92.85, marking an increase of 1.33.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.20. This value is within the healthy range. It has decreased from 3.55 (Mar 24) to 3.20, marking a decrease of 0.35.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.12. This value is below the healthy minimum of 3. It has decreased from 2.30 (Mar 24) to 2.12, marking a decrease of 0.18.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5,163.72. It has increased from 3,526.29 (Mar 24) to 5,163.72, marking an increase of 1,637.43.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.37. This value is within the healthy range. It has increased from 1.07 (Mar 24) to 1.37, marking an increase of 0.30.
- For EV / EBITDA (X), as of Mar 25, the value is 9.83. This value is within the healthy range. It has increased from 8.24 (Mar 24) to 9.83, marking an increase of 1.59.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1. It has increased from 0.71 (Mar 24) to 0.91, marking an increase of 0.20.
- For Retention Ratios (%), as of Mar 25, the value is 89.27. This value exceeds the healthy maximum of 70. It has increased from 86.57 (Mar 24) to 89.27, marking an increase of 2.70.
- For Price / BV (X), as of Mar 25, the value is 1.52. This value is within the healthy range. It has increased from 1.14 (Mar 24) to 1.52, marking an increase of 0.38.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1. It has increased from 0.71 (Mar 24) to 0.91, marking an increase of 0.20.
- For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 24) to 0.06, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in India Glycols Ltd:
- Net Profit Margin: 4.89%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.64% (Industry Average ROCE: 8.17%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.23% (Industry Average ROE: 9.9%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.12
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.27
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 24.6 (Industry average Stock P/E: 26.9)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.79
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.89%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Beverages & Distilleries | 6A-1, Industrial Area, Bazpur Road, Udham Singh Nagar Uttarakhand/Uttaranchal 244713 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. U S Bhartia | Chairman & Managing Director |
| Mr. Pragya Bhartia Barwale | Executive Director |
| Mr. Alok Singhal | Executive Director |
| Mr. Sushil Dutt Salwan | Independent Director |
| Mr. Samrat Banerjee | Independent Director |
| Mrs. Jayshree Bhartia | Director |
| Mr. Ravi Kumar | Independent Director |
| Ms. Shukla Wasson | Independent Director |
FAQ
What is the intrinsic value of India Glycols Ltd?
India Glycols Ltd's intrinsic value (as of 11 February 2026) is ₹742.38 which is 25.09% lower the current market price of ₹991.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹6,649 Cr. market cap, FY2025-2026 high/low of ₹1,223/502, reserves of ₹2,363 Cr, and liabilities of ₹6,157 Cr.
What is the Market Cap of India Glycols Ltd?
The Market Cap of India Glycols Ltd is 6,649 Cr..
What is the current Stock Price of India Glycols Ltd as on 11 February 2026?
The current stock price of India Glycols Ltd as on 11 February 2026 is ₹991.
What is the High / Low of India Glycols Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of India Glycols Ltd stocks is ₹1,223/502.
What is the Stock P/E of India Glycols Ltd?
The Stock P/E of India Glycols Ltd is 24.6.
What is the Book Value of India Glycols Ltd?
The Book Value of India Glycols Ltd is 357.
What is the Dividend Yield of India Glycols Ltd?
The Dividend Yield of India Glycols Ltd is 0.50 %.
What is the ROCE of India Glycols Ltd?
The ROCE of India Glycols Ltd is 12.4 %.
What is the ROE of India Glycols Ltd?
The ROE of India Glycols Ltd is 11.1 %.
What is the Face Value of India Glycols Ltd?
The Face Value of India Glycols Ltd is 5.00.